131 related articles for article (PubMed ID: 9876815)
1. Irinotecan: a new antineoplastic agent for the management of colorectal cancer.
Cersosimo RJ
Ann Pharmacother; 1998 Dec; 32(12):1324-33. PubMed ID: 9876815
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Conti JA; Kemeny NE; Saltz LB; Huang Y; Tong WP; Chou TC; Sun M; Pulliam S; Gonzalez C
J Clin Oncol; 1996 Mar; 14(3):709-15. PubMed ID: 8622015
[TBL] [Abstract][Full Text] [Related]
5. A risk-benefit assessment of irinotecan in solid tumours.
Siu LL; Rowinsky EK
Drug Saf; 1998 Jun; 18(6):395-417. PubMed ID: 9638386
[TBL] [Abstract][Full Text] [Related]
6. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.
Kramar A; Gourgou-Bourgade S; Ychou M
J Clin Oncol; 2005 Jan; 23(3):650; author reply 650-1. PubMed ID: 15659517
[No Abstract] [Full Text] [Related]
7. Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer.
Paulík A; Grim J; Filip S
Acta Medica (Hradec Kralove); 2012; 55(4):153-9. PubMed ID: 23631285
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan in the first-line treatment of colorectal cancer.
Saltz LB
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):54-8. PubMed ID: 9726092
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer.
Berg D
Oncol Nurs Forum; 1998 Apr; 25(3):535-43. PubMed ID: 9568608
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between UGT1A and irinotecan-related toxicity].
Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):241-3. PubMed ID: 23985249
[No Abstract] [Full Text] [Related]
11. New agents in gastrointestinal malignancies: Part 1: Irinotecan in clinical practice.
Stucky-Marshall L
Cancer Nurs; 1999 Jun; 22(3):212-9. PubMed ID: 10376382
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Delioukina ML; Prager D; Parson M; Hecht JR; Rosen P; Rosen LS
Cancer; 2002 Apr; 94(8):2174-9. PubMed ID: 12001114
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
Prescrire Int; 2001 Apr; 10(52):41-3. PubMed ID: 11718156
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan for metastatic colorectal cancer.
Med Lett Drugs Ther; 1997 Jan; 39(992):8. PubMed ID: 9008684
[No Abstract] [Full Text] [Related]
16. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients.
Yumuk PF; Aydin SZ; Dane F; Gumus M; Ekenel M; Aliustaoglu M; Karamanoglu A; Sengoz M; Turhal SN
Int J Colorectal Dis; 2004 Nov; 19(6):609-10. PubMed ID: 15293062
[No Abstract] [Full Text] [Related]
17. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
Rothenberg ML
Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
[TBL] [Abstract][Full Text] [Related]
18. Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.
Tadokoro J; Kakihata K; Shimazaki M; Shiozawa T; Masatani S; Yamaguchi F; Sakata Y; Ariyoshi Y; Fukuoka M
Jpn J Clin Oncol; 2011 Sep; 41(9):1101-11. PubMed ID: 21852251
[TBL] [Abstract][Full Text] [Related]
19. Colorectal cancer: dilemmas regarding patient selection and toxicity prediction.
Nikolic-Tomasevic Z; Jelic S; Popov I; Radosavljevic D
J Chemother; 2000 Jun; 12(3):244-51. PubMed ID: 10877521
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan: toward clinical end points in drug development.
Pazdur R
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
